Can a targeted drug shrink Hard-to-Treat thymic tumors?
NCT ID NCT07750353
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This phase II trial is testing whether an experimental drug called sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with thymic carcinoma that cannot be surgically removed and has already been treated with platinum-based chemotherapy. Participants receive the drug intravenously every two weeks for up to about three years, and the study tracks how many patients see their tumors shrink. The goal is to see if this targeted therapy offers a new option for a rare cancer with limited treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab tirumotecan (Sac-TMT), an antibody-drug conjugate given intravenously
- What this could lead to
- If effective, this could offer a new treatment option for people with thymic carcinoma that cannot be removed by surgery and has progressed after standard chemotherapy.
- What could go wrong
- This is a small, early-phase study (35 participants) without a comparison group, so results may not be conclusive. The drug can cause side effects, and it is not yet known if it will work better than existing options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
Osaka International Cancer Institute
Chuo-ku, Osaka, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.